TABLE 3.
Author (year) | Study cohort | Geriatric assessment tool/cut‐off value (% of frail patients) | Postoperative complications | Postoperative mortality | Length of hospital stay | Patient survival |
---|---|---|---|---|---|---|
HCC | ||||||
Ishihara et al (2021) |
|
|
↑ (Postoperative delirium, 15% vs 1.8%, P < 0.001) |
– | – | – |
Kaibori et al (2021) |
|
|
NS | – | – |
↓ OS: HR 8.1 (95%CI, 4.0‐16.3) RFS: HR 5.4 (95%CI, 3.2‐9.0) |
Yamada et al (2021) |
|
|
NS | NS | NS |
↓ CSS: HR 7.9 (95%CI, 1.6‐38.1) |
Tanaka et al (2018) |
|
|
↑ (Bile leakage, 11% vs 3.2%, P = 0.021; delirium, 13% vs 1.9%, P = 0.003) |
↑ (90‐day mortality, 4.8% vs 0%, P = 0.024) |
‐ | ‐ |
Kaibori et al (2016) |
|
|
↑ (CD ≥II, 44% vs 3%, P < 0.001) |
NS |
↑ (Postoperative hospital stay ≥13 days, 67% vs 38%, P = 0.014) |
‐ |
Pancreatic cancer | ||||||
Mima et al (2021) |
|
|
NS | NS | – |
↓ OS: HR 2.3 (95%CI, 1.1‐4.4) CSS: HR 2.5 (95%CI, 1.1‐5.3) |
Ngo‐Huang et al (2019) |
|
|
– | – | – |
↓ (P = 0.038) |
Mogal et al (2017) |
|
|
↑ (CD III/IV, 41% vs 29%, P < 0.001) |
↑ (6.3% vs 2.7%, P < 0.001) |
‐ | ‐ |
Augustin et al (2016) |
|
|
↑ (CD IV, PD: 37% vs 7.1%, P < 0.001; DP, 28% vs 3.4%, P < 0.001) |
↑ (PD, 22% vs 1.6%, P < 0.001; DP, 11% vs 0.6%, P < 0.001) |
↑ (PD, 20 days vs 13 days, P < 0.001; DP, 17 days vs 8 days, P < 0.001) |
‐ |
Dale et al (2014) |
|
|
↑ (CD ≥III, OR, 4.1, P = 0.01) |
– |
↑ (P = 0.02) |
‐ |
Note: ↑, higher incidence of postoperative complications or mortality, and longer length of hospital stay in frail patients; ↓, shorter overall, cancer‐specific, or recurrence‐free survival in frail patients; −, not examined.
Abbreviations: CD, Clavien‐Dindo grade; CI, confidence interval; CSS, cancer‐specific survival; DP, distal pancreatectomy; HCC, hepatocellular carcinoma; HR, hazard ratio; NS, not significant (P > 0.05); OS, overall survival; PD, pancreaticoduodenectomy.